RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
Sponsor
Repligen Corporation (Industry)
Overall Status
Terminated
CT.gov ID
NCT00060515
Collaborator
(none)
12
Study Details
Study Description
Brief Summary
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Primary Purpose:
Treatment
Official Title:
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
3 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Mitochondrial Disease
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Repligen Corporation
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00060515
Other Study ID Numbers:
- RG2133-01
First Posted:
May 8, 2003
Last Update Posted:
Aug 5, 2005
Last Verified:
Aug 1, 2005
Additional relevant MeSH terms: